Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-32.22%
operating margin TTM
-7.06%
revenue TTM
204.44 Million
revenue per share TTM
1.03$
valuation ratios | |
|---|---|
| pe ratio | -7.95 |
| peg ratio | 3.90 |
| price to book ratio | -1.73 |
| price to sales ratio | 2.56 |
| enterprise value multiple | -25.55 |
| price fair value | -1.73 |
profitability ratios | |
|---|---|
| gross profit margin | 14.31% |
| operating profit margin | -7.06% |
| pretax profit margin | -32.22% |
| net profit margin | -32.22% |
| return on assets | -26.89% |
| return on equity | 23.04% |
| return on capital employed | -430.04% |
liquidity ratios | |
|---|---|
| current ratio | 1.00 |
| quick ratio | 0.70 |
| cash ratio | 0.26 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 304.92 |
| operating cycle | 447.87 |
| days of payables outstanding | 0.00 |
| cash conversion cycle | 447.87 |
| receivables turnover | 2.55 |
| payables turnover | 0.00 |
| inventory turnover | 1.20 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.42 |
| debt equity ratio | -0.34 |
| long term debt to capitalization | -0.51 |
| total debt to capitalization | -0.51 |
| interest coverage | 0.47 |
| cash flow to debt ratio | -0.62 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.47 |
| cash per share | 0.47 |
| operating cash flow per share | -0.47 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -0.62 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
When was the last time Esperion Therapeutics, Inc. (NASDAQ:ESPR) reported earnings?
Esperion Therapeutics, Inc. (ESPR) published its most recent earnings results on 06-11-2025.
What is Esperion Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Esperion Therapeutics, Inc. (NASDAQ:ESPR)'s trailing twelve months ROE is 23.04%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Esperion Therapeutics, Inc. (ESPR) currently has a ROA of -26.89%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ESPR's net profit margin stand at?
ESPR reported a profit margin of -32.22% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ESPR's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.00 in the most recent quarter. The quick ratio stood at 0.70, with a Debt/Eq ratio of -0.34.